Clinical trials: From bench to bedside to improve outcomes for cancer patients
Clinical trials are crucial to understanding how drugs and therapies work, how safe they are in humans, and how effective they are in treating cancer. They are vital for making...
January 18, 2023
No Comments
Cancer – the hallmarks and beyond
Although cancer represents a huge challenge for our healthcare systems, new immunotherapies and other advanced novel treatments mean hope is on the horizon. Cancer is one of the all-pervading topics...
September 26, 2022
No Comments
Three questions to Mario Kuttke, Head of Cell Therapy
1. Do cell therapies represent a breakthrough in cancer treatment? Mario Kuttke: It is really amazing how adoptive cell therapy (ACT), a form of cancer immunotherapy, has evolved so rapidly...
July 27, 2022
No Comments
The race against cancer – targeting Cbl-b in cellular therapy
invIOs’s novel clinical stage lead therapeutic candidate, APN401, combines advances in immune cell therapy and RNA interference methods to treat advanced solid cancers. Immune therapy – hitting new targets Immune...
June 29, 2022
No Comments
Three questions to Alexander Dohnal, Head of Preclinical Development
1. Ribonucleic acids have for a long time been DNA’s “little sister”. What’s so different between RNA and DNA? Alexander Dohnal: RNA and DNA have a lot in common. Chemical...
April 5, 2022
No Comments
RNA – in the midst of a medical revolution
Ribonucleic acid (RNA) therapies are promising to change the way we treat diseases. From cancer therapies to vaccines and treatments for genetic diseases, the opportunities are almost infinite.
April 5, 2022
No Comments
Unlocking the master checkpoint of cancer immunity
Our knowledge of cancer is growing daily, bringing with it new treatment strategies. As mentioned previously (here) novel immunotherapies are at the forefront of cancer research. The immune activating monoclonal…
January 28, 2022
No Comments
Three questions to Romana Gugenberger, Chief Medical and Scientific Officer
1. Despite novel immune-therapies against cancer there are still non-responders and relapses. Why is that? Romana Gugenberger: Tumors are heterogeneous. Additionally, tumors are not static but evolve. Once a response…
January 28, 2022
No Comments
- 1
- 2
